SARA SIEGFRIED: Open Payments
NPI 1467941120 · DAYTONA BEACH, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$273 in 11 payments from 10 companies in 2025. Trend: 2023 $102 · 2024 $421 · 2025 $273
Food & beverage: $273
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 2 | $57 |
| Janssen Scientific Affairs, LLC | 1 | $37 |
| Astellas Pharma US Inc | 1 | $33 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Geron Corporation | 1 | $23 |
| Genentech USA, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Incyte Corporation | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $16 |
Products named: RYBREVANT, Vyloy, KISQALI, SCEMBLIX, OPDIVO, FRUZAQLA, RYTELO, Venclexta.
Industry payments across FL — which companies pay providers there.
